ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Augmedix is an ambient AI healthcare optimization play

doctor reviewing notes with patient

Augmedix Inc. (NASDAQ: AUGX) is an artificial intelligence (AI) powered ambient medical documentation solutions provider in the medical sector. It utilizes generative AI for documenting medical records and transcribing medical notes and conversations, which are seamlessly integrated into the electronic health record (EHR) system used by healthcare systems, insurers, offices, and practices. Accurately and comprehensively documenting medical notes is a burdensome and time-consuming task for medical providers.

Improvement metrics

Augmedix optimizes provider workflows by automating the medical documenting process using ambient AI. Doctors can spend up to 25% of a patient's visit documenting the medical notes. Freeing up this time means more time spent with patients and less time spent writing (legibly) in a patient's chart. According to the company, providers save up to three hours per day and increase productivity by 20% while improving work-life satisfaction by 40% and patient satisfaction by 35%.

Consequences of illegible handwriting.

Doctors aren't known to have the best handwriting. Due to time constraints, efficiency, medical jargon, and habits, ineligible doctor's notes can have serious consequences in healthcare. These can range from misinterpretation of treatment plans and medical doses, delays in patient care due to deciphering notes, increased potential for medical errors and overall frustration amongst patients and staff.

This is one of the reasons behind the push for electronic health records (EHR), which provides convenient access to medical records as well as legibility. However, the process of manually transcribing or typing in medical notes and documentation can be time-consuming, resulting in longer wait times and delayed care. Get AI-powered insights on MarketBeat.

The Augmedix solution

Augmedix automatically transcribes medical notes and natural conversations into medical records. Captured audio is converted into structured medical notes that automatically document significant details, including medications, diagnoses, treatment plans, and procedures. This results in more accurate notes and optimizes providers' time as they spend less effort on burdensome administrative tasks and charting and more time with patients. Augmedix also provides data services that generate additional insights, including quality metrics and performance analytics.

HCA Healthcare validates the technology

The nation's largest hospital system, HCA Healthcare Inc. (NYSE: HCA), has undertaken a pilot program for doctors to use Augmedix Go to produce medical records through the Alphabet Inc. (NASDAQ: GOOGL) Google Cloud. The program is being integrated into 75 emergency departments at four HCA hospitals. Providers will use the Augmedix app on a hands-free device to record and transcribe patient engagements to extract, transcribe and transform conversations into medical notes.

Doctors can review the notes to verify accuracy before transferring the information into the patient's EHR. Feedback has been positive. Emergency departments are chaotic, with different doctors taking over patient care coverage. The accuracy of medical notes is paramount. HCA believes in the service so much that it's also an investor in Augmedix. Check out the sector heatmap on MarketBeat.

Preliminary Q4 2023 update

On January 5, 2024, Augmedix provided preliminary revenue results and operational metrics for Q4 2023. The company expects Q4 2023 revenues of around $12.5 million and full-year 2023 revenues of approximately $44.7 million. Annual recurring revenue (ARR) rose 46% YoY to 51 million. Clinicians using the service rose 41% YoY to 1,830. Augmedix Go went live for ambulatory setting in mid-December. The actual Q4 2023 release is expected in March 2024.

Augmedix CEO Manny Krakaris commented, "Augmedix is committed to playing an essential role in unburdening clinicians and improving the operating efficiency of healthcare organizations. We have assembled the industry's broadest portfolio of documentation solutions, tailored to a range of healthcare settings, from primary care physician visits to emergency medicine to mental health sessions."

Krakaris continued, "Our ability to provide the right technology, with the appropriate level of human intervention and machine learning, gives us a durable competitive advantage within this rapidly evolving industry.

Augmedix analyst ratings and price targets are at MarketBeat. Augmedix peers and competitor stocks can be found with the MarketBeat stock screener.

augx stock daily ascending triangle

Daily ascending triangle pattern     

The daily candlestick chart on AUGX illustrates an ascending triangle pattern. The flat-top upper horizontal trendline resistance is at $5.99. The lower ascending trendline commenced off the $3.98 lows on November 16, 2023. The daily 50-period moving average support is rising at $5.30, followed by the 200-period moving average support at $4.39. The daily relative strength index (RSI) has fallen back under the 50-band. Pullback support levels are at $5.28, $4.62, $3.98 and $3.61.  

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.